top of page

Antibiotics Reveal a COVID Pathway

I published a couple of blogs during COVID-19 highlighting some experts who discussed bacterial pathways during COVID-19 and how antibiotics helped.

Lewis Note: I now confidently suggest a natural antibiotic regimen that has been proven to work very well. However, it's important to note that in very late-stage cases, regardless of the condition, pharmaceuticals may still be beneficial. Remember, ivermectin IS a pharmaceutical!

Here are those blogs.


Now comes a very interesting article documenting positive outcomes in COVID by several doctors using antibiotic therapy as part of their regiment.

I suggest you read the article. Below, I am reproducing just part of the article. The part I am not including is how governments recommended against antibiotic use. That tells a lot. You should know by now that doing just the opposite of these types of recommendations is often the right path!


Physicians defying public health authorities

When physicians chose to use antibiotics to treat patients in defiance of public health authorities, they reported some startling results.

Physicians in Toledo, Spain, empirically administered antibiotics to covid-19 patients during spring 2020, contrary to official guidance. This resulted in zero hospitalizations or deaths in their care homes after they started routine administration. Their resulting mortality over spring 2020 was approx. 7% versus 28% in other comparable care homes (and the 7% died before they started routine antibiotic use).

Likewise in Romania a physician, Flavia Groșan, was reported in the media as approaching covid-19 as “atypical pneumonia”, saying there were huge mistakes with excessive oxygen therapy and intubation:

“Too much oxygen for too lengthy periods at a time, says Groșan, can lead to cerebral edema which in turn can cause death.”

She gave her patients ‘enough’ oxygen for their needs, antibiotics and other cheap medicines. On the choice of antibiotics, she said:

“There are only three antibiotics in the macrolide class, erythromycin, which everyone knows, azithromycin and clarithromycin. I don’t like azithromycin because it’s a weaker copy of clarithromycin. I worked in some very interesting clinical studies on pneumonia and there I learned about the viral tropism of clarithromycin, as well as the anti-inflammatory role of clarithromycin, which no antibiotic has.
I have been working with this antibiotic in viral and atypical pneumonias for 10 years. When the pandemic hit I went for an etiological treatment, clarithromycin. Of course, in addition to this antibiotic, there are several adjuvant treatments, because it can’t cope alone. It is a treatment scheme that is my own.”

Lewis Comment: These drugs may not treat virals, but there is almost always comorbid bacterial infections. If we can reduce your bacterial burden, maybe your immune system can begin to overcome the (weaker?) virals.

She reported healing 100% of some 1,000 patients using this approach.

At St Paul’s hospital in Vancouver, Canada, Russell and Walley learned that Covid-19 is not deadly in itself, but it is sepsis that causes the organ failure leading to death. In this article they say:

“The pandemic we’ve all been living through is actually a pandemic of sepsis due to COVID-related pneumonia.  Everybody who dies of COVID actually dies of sepsis and pneumonia. Everybody.”

Sepsis is the number one cause of death worldwide. They go on to emphasise the importance of antibiotics and other measures in treating Covid-19:

It’s a complex syndrome that can require antibiotics, oxygen, drugs to stabilize blood pressure, and dialysis to support failing kidneys. In addition to this, there’s also no diagnostic test available to detect sepsis, making the diagnosis a challenge. 

Ivermectin protocols as antibiotic treatments

The various protocols for use of ivermectin as an early treatment and prophylactic for covid-19 also include the administration of antibiotics, such as doxycycline and azithromycin, as documented in the Zelenko protocol:

And of course, ivermectin is reported to have antimicrobial policies, in itself, as documented here.

Finally, there is this evidence that chloroquine is a potent treatment for SARS.

Note that these protocols recommend antibiotics for high-risk patients. Those are the same patients who may be likely suffering from bacterial pneumonia.

It is worth pointing out that ivermectin and many antibiotics often have antioxidant or anti-inflammatory properties that will also help when treating viral and bacterial infections. This is the case with azithromycin and a cursory search of pubMed results in 58 papers on the topic.

Antibiotics and the common cold

A fascinating letter appeared in the Proceedings of the Royal Society of Medicine in 1958 written by a Dr J. Morrison Ritchie in response to an article on the common cold by Hope Simpson3. In it he describes a study carried out at the Birkenhead Public Health Laboratory on 1,000 volunteers in the winter of 1955/56 where they applied antibiotics for patients suffering cold symptoms. They reported that:

There were 22/581 colds among those receiving antibiotic tablets on the first day, as against 87/338 among those receiving inert control tablets: 3.8 % as against 25.7%, a drop to one-seventh. In the adult industrial population, the proportion was one to nine, and this drop was evident in all the units of the investigation.

Clearly many colds were not viral infections at all but bacterial infections, but such is the overlap in observed respiratory symptoms for these broad classes of pathogen, that absent the administration of antibiotics, this would have escaped attention.

If physicians can easily confuse common cold infections with bacterial infections what is to say they will be able to differentiate between SARS-CoV-2 and bacterial pneumonia?

The use of face coverings may have magnified the harms

The possibility must be raised that the widespread use of face coverings was synergistically harmful when combined with a deliberate policy of restricting antibiotic use.

It has long been recognised that bacterial pneumonia frequently caused by so-called “commensal” bacteria - i.e., those which normally colonise the nose and mouth.

Hence it was not at all surprising that colonies of such bacteria (as well as fungi) were found on nearly all the face coverings used by the volunteers in this study performed in Japan, published in Nature.

The less effective immune system of the elderly is yet another factor which could have acted synergistically with the above to increase the likelihood of them developing bacterial pneumonia under the policies imposed.



Azithromycin is a commonly used macrolide antibiotic that has antiviral properties mainly attributed to reduced endosomal transfer of virions as well as established anti-inflammatory effects.

It has been commonly used in COVID-19 studies initially based on French reports demonstrating markedly reduced durations of viral shedding, fewer hospitalizations, and reduced mortality combination with HCQ as compared to those untreated.

In the large inpatient study (n = 2451) discussed previously, those who received azithromycin alone had an adjusted HR for mortality of 1.05, 95% CI 0.68-1.62, and P = 0.83.

The combination of HCQ and azithromycin has been used as standard of care in other contexts as a standard of care in more than 300,000 older adults with multiple comorbidities.

This agent is well-tolerated and like HCQ can prolong the QTc in <1% of patients. The same safety precautions for HCQ listed previously could be extended to azithromycin with or without HCQ. Azithromycin provides additional coverage of bacterial upper respiratory pathogens that could potentially play a role in concurrent or secondary infection. Thus, this agent can serve as a safety net for patients with COVID-19 against clinical failure of the bacterial component of community-acquired pneumonia.

The same safety precautions for HCQ could be extended to azithromycin with or without HCQ. Because both HCQ and azithromycin have small but potentially additive risks of QTc prolongation, patients with known or suspected arrhythmias or taking contraindicated medications or should have more thorough workup (eg, review of baseline electrocardiogram, imaging studies, etc.) before receiving these 2 together. One of many dosing schemes is 250 mg po bid for 5 days and may extend to 30 days for persistent symptoms or evidence of bacterial superinfection.


Doxycycline is another common antibiotic with multiple intracellular effects that may reduce viral replication, cellular damage, and expression of inflammatory factors.

This drug has no effect on cardiac conduction and has the main caveat of gastrointestinal upset and esophagitis. As with azithromycin, doxycycline has the advantage of offering antibacterial coverage for superimposed bacterial infection in the upper respiratory tract. Doxycycline has a high degree of activity against many common respiratory pathogens including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, anaerobes such as Bacteroides and anaerobic/microaerophilic streptococci and atypical agents like Legionella, Mycoplasma pneumoniae, and Chlamydia pneumoniae.

One of many dosing schemes is 200 mg po followed by 100 mg po bid for 5 days and may extend to 30 days for persistent symptoms or evidence of bacterial superinfection. Doxycycline may be useful with HCQ for patients in whom the HCQ-azithromycin combination is not desired.


Weekly Webinar Links: Join us for detailed health information - at no charge. All are welcome.

Monday at noon EST -

Wednesday at 8 pm EST -


Be Bold - Be Brave - Stay Well


278 views0 comments

Recent Posts

See All


bottom of page